A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75-Reference-Cited by-同舟云学术

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75

Published:2023-01 Issue:1 Volume:42 Page:111903
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Huo Jiandong,Dijokaite-Guraliuc Aiste,Liu Chang,Zhou Daming,Ginn Helen M.,Das Raksha,Supasa Piyada,Selvaraj Muneeswaran,Nutalai Rungtiwa,Tuekprakhon Aekkachai,Duyvesteyn Helen M.E.,Mentzer Alexander J.,Skelly Donal,Ritter Thomas G.,Amini Ali,Bibi Sagida,Adele Sandra,Johnson Sile Ann,Paterson Neil G.,Williams Mark A.,Hall David R.,Plowright Megan,Newman Thomas A.H.,Hornsby Hailey,de Silva Thushan I.,Temperton Nigel,Klenerman Paul,Barnes Eleanor,Dunachie Susanna J.,Pollard Andrew J.,Lambe Teresa,Goulder Philip,Fry Elizabeth E.,Mongkolsapaya Juthathip,Ren Jingshan,Stuart David I.^ORCID,Screaton Gavin R.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference46 articles.

1. Coronavirus RNA proofreading: molecular basis and therapeutic targeting;Robson;Mol. Cell,2020

2. Clinical and infection prevention applications of severe acute respiratory syndrome coronavirus 2 genotyping: an infectious diseases society of America/American society for microbiology consensus review document;Greninger;J. Clin. Microbiol.,2022

3. Analysis of 6.4 million SARS-CoV-2 genomes identifies mutations associated with fitness;Obermeyer;Science,2022

4. Recent developments in SARS-CoV-2 vaccines: a systematic review of the current studies;Sadeghalvad;Rev. Med. Virol.,2022

5. Monoclonal antibody therapies against SARS-CoV-2;Focosi;Lancet Infect. Dis.,2022

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SARS-CoV-2 infectivity and antigenic evasion: spotlight on isolated Omicron sub-lineages;Frontiers in Medicine;2024-08-29

2. A structure-function analysis shows SARS-CoV-2 BA.2.86 balances antibody escape and ACE2 affinity;Cell Reports Medicine;2024-05

3. Anti-SARS-CoV-2 glyco-humanized polyclonal antibody XAV-19: phase II/III randomized placebo-controlled trial shows acceleration to recovery for mild to moderate patients with COVID-19;Frontiers in Immunology;2024-04-17

4. Ensemble-Based Mutational Profiling and Network Analysis of the SARS-CoV-2 Spike Omicron XBB Lineages for Interactions with the ACE2 Receptor and Antibodies: Cooperation of Binding Hotspots in Mediating Epistatic Couplings Underlies Binding Mechanism and Immune Escape;International Journal of Molecular Sciences;2024-04-12

5. Predicting Functional Conformational Ensembles and Binding Mechanisms of Convergent Evolution for SARS-CoV-2 Spike Omicron Variants Using AlphaFold2 Sequence Scanning Adaptations and Molecular Dynamics Simulations;2024-04-03